CGS 25462: a neutral endopeptidase (NEP) inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 132812 |
| CHEMBL ID | 147342 |
| SCHEMBL ID | 7312208 |
| MeSH ID | M0228447 |
| Synonym |
|---|
| 147862-03-1 |
| beta-alanine, n-(3-(1,1'-biphenyl)-4-yl-n-((diphenoxyphosphinyl)methyl)-l-alanyl)- |
| up2r15wbf4 , |
| 3-(n-(2-(((diphenylphosphono)methyl)amino)-3-(4-biphenylyl)propionyl)amino)propionic acid |
| unii-up2r15wbf4 |
| cgs 25462 |
| cgs-25462 |
| CHEMBL147342 |
| SCHEMBL7312208 |
| (s)-n-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)propionyl]-3-aminopropionic acid |
| (s)-n-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)-propionyl]-3-aminopropionic acid |
| JTQWXNZXTRVPHN-LJAQVGFWSA-N |
| DTXSID10933234 |
| n-[3-([1,1'-biphenyl]-4-yl)-2-{[(diphenoxyphosphoryl)methyl]amino}-1-hydroxypropylidene]-beta-alanine |
| 3-(1,1'-biphenyl)-4-yl-n-((diphenoxyphosphinyl)methyl)-l-alanyl-.beta.-alanine |
| .beta.-alanine, 3-(1,1'-biphenyl)-4-yl-n-((diphenoxyphosphinyl)methyl)-l-alanyl- |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID229589 | Ratio of maximum plasma concentration (C) measured ex vivo to that of IC50 of (10a or 10c) in rat treated intravenously with 10 mg/kg | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. |
| AID328935 | Chemical stability assessed as half life of hydrolysis in carbonate buffer at pH 8.5 | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Prodrugs of phosphates and phosphonates. |
| AID328934 | Chemical stability assessed as half life of hydrolysis in phosphate buffer at pH 8.5 | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Prodrugs of phosphates and phosphonates. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||